CXCR4 and prostate carcinoma: Moreover, while the activation of Wnt/β-catenin and SDF-1/CXCR4 signaling was supported by molecular evidence, the precise functional consequences of pharmacological inhibition of these pathways in different prostate cancer subtypes and stromal contexts warrant further investigation.